Matching articles for "Palonosetron"
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • December 28, 2020; (Issue 1614)
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • November 18, 2019; (Issue 1585)
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
The Medical Letter on Drugs and Therapeutics • December 3, 2018; (Issue 1561)
The FDA has approved Cinvanti (Heron), an IV
emulsion formulation of the substance P/neurokinin-1
(NK1) receptor antagonist aprepitant, for prevention
of acute and delayed chemotherapy-induced nausea
and...
The FDA has approved Cinvanti (Heron), an IV
emulsion formulation of the substance P/neurokinin-1
(NK1) receptor antagonist aprepitant, for prevention
of acute and delayed chemotherapy-induced nausea
and vomiting (CINV) in adults. Aprepitant is also
available in oral capsule and suspension formulations
(Emend, and generics), and fosaprepitant, a prodrug of
aprepitant, is available in an IV formulation (Emend for
injection).
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • August 1, 2016; (Issue 1500)
In the US, 25 states and the District of Columbia now
permit some medical use of botanical marijuana
(Cannabis sativa). It has been used for centuries to treat
various ailments, but non-standardization of...
In the US, 25 states and the District of Columbia now
permit some medical use of botanical marijuana
(Cannabis sativa). It has been used for centuries to treat
various ailments, but non-standardization of dosage
makes available data difficult to interpret. Cannabis
contains >60 pharmacologically active cannabinoids.
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • February 1, 2016; (Issue 1487)
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with...
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with cancer
chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) and netupitant (only available
in combination with the 5-HT3 receptor antagonist
palonosetron as Akynzeo) were approved earlier for
prevention of both acute and delayed chemotherapy-induced
nausea and vomiting.
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • April 27, 2015; (Issue 1467)
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist palonosetron,
for prevention of acute and delayed nausea and
vomiting associated with cancer chemotherapy
in adults. Akynzeo is the first product to combine
drugs from these two classes. Palonosetron (Aloxi)
is also available as a single agent for prevention of
chemotherapy-induced and postoperative nausea
and vomiting. Netupitant is the second substance
P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) was the first.
A Granisetron Patch (Sancuso)
The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor...
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation (Sancuso - ProStrakan).
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • March 29, 2004; (Issue 1179)
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and dexamethasone to prevent both acute and delayed nausea and vomiting due to highly emetogenic drugs (Medical Letter 2003; 45:62).